RxDoctor Payments Data

Genise Green

Nurse Practitioner · West Mifflin, PANPI 1265768329

Payments from drug & device makers

$5,906in general payments, 2019–2025

Across 50 payments — averaging $118.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • AstraZeneca$314
  • Amgen$256
  • Bridgebio Pharma, Inc.$238
  • Sanofi$53
  • plus $11 from 1 others

What the payments were for

  • Consulting fees$2,08135%
  • Travel & lodging$1,41524%
  • Food & beverage$2,41041%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,906 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$13,008
Medicare patients
86
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis191$4,273,229
CamzyosMavacamten145$1,194,506
VyndaqelTafamidis Meglumine13$300,950
JardianceEmpagliflozin58$51,340
EliquisApixaban53$51,237
FarxigaDapagliflozin Propanediol12$9,220
Disopyramide Phosphate35$7,897
Potassium Chloride31$1,047
Torsemide47$705
Bumetanide14$472
Spironolactone54$417
Furosemide29$356
Metoprolol Succinate31$333
Metoprolol Tartrate23$237
Rosuvastatin Calcium11$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$1,929$1,194,506145 claims
AstraZenecaFarxiga$314$9,22012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in West Mifflin

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →